Results 91 to 100 of about 21,799 (237)

Recurrent Respiratory Papillomatosis Foundation Position Statement on the Management of Adults With RRP

The Laryngoscope, EarlyView.
ABSTRACT Objective With regulatory approval of HPV‐specific immunotherapy for recurrent respiratory papillomatosis (RRP) and growing experience with systemic bevacizumab, a management algorithm incorporating these medical treatments is warranted. Data Sources and Methods RRP Foundation (RRPF) Key Opinion Leaders offer a proposed management algorithm ...
Simon R. Best, Aaron D. Friedman, Clark A. Rosen, Robert T. Sataloff, Laura A. Matrka, H. Steven Sims, David E. Rosow, Nabil F. Saba, David G. Lott, Adam M. Klein, Ted Mau, Milan R. Amin, Kathryn A. Wikenheiser‐Brokamp, Scott M. Norberg, Kim McClellan, Geoffrey D. Young, Clint T. Allen, on behalf of the Recurrent Respiratory Papillomatosis Foundation   +17 more
wiley   +1 more source

Budget impact analysis of natalizumab biosimilar on pharmaceutical expenditure for the treatment of relapsing-remitting multiple sclerosis in Italy

AboutOpen
Background: The availability of high-efficacy disease-modifying therapy (DMT), including natalizumab, improved treatment efficacy in adults with highly-active relapsing-remitting multiple sclerosis (RRMS).
Roberto Bergamaschi, Marco Capobianco , Roberto Ravasio   +2 more
doaj   +1 more source

A phase III, randomized, two-armed, double-blind, parallel, active controlled, and non-inferiority clinical trial to compare efficacy and safety of biosimilar adalimumab (CinnoRA (R)) to the reference product (Humira (R)) in patients with active rheumatoid arthritis [PDF]

, 2017
Background: This study aimed to compare efficacy and safety of test-adalimumab (CinnoRA (R), CinnaGen, Iran) to the innovator product (Humira (R), AbbVie, USA) in adult patients with active rheumatoid arthritis (RA).
Ahmadzadeh, Arman., Ebrahimi, Ali Asghar., Gharibdoost, Farhad., Hajiabbasi, Asghar., Jamshidian, Ahmadreza., Karimzadeh, Hadi., Mahjourian, Najmeh., Mohammadinejad Rashti, Amin., Mousavi, Mohammad., Nazarinia, Mohammad Ali., Rezaieyazdi, Zahra., Sahebari, Maryam., Shakibi, Mohammad Reza., Soroosh, Soosan.G., Soroush, Mohsen., Vojdanian, Mahdi.   +15 more
core   +1 more source

Respiratory Syncytial Virus (RSV): A Comprehensive Overview From Basic Biology to Clinical Prevention and Control

Medicinal Research Reviews, EarlyView.
ABSTRACT Respiratory syncytial virus (RSV) is a common virus that causes respiratory infections, posing a serious threat, particularly to infants, the elderly, and individuals with compromised immune systems. As the leading cause of lower respiratory tract infections (LRTIs) in infants, RSV is responsible for millions of cases worldwide each year.
Jie Shi, Xiya Huang, Chunjun Ye, Yishan Lu, Yanyan Liu, Yuquan Wei, Xiawei Wei   +6 more
wiley   +1 more source

Prediction of short- and medium-term efficacy of biosimilar infliximab therapy. Do trough levels/antidrug antibody levels or clinical/biochemical markers play a more important role? [PDF]

, 2018
K
Bene, László, Bor, Renáta, Bíró, Edina, Farkas, Klaudia, Gasztonyi, Beáta, Gecse, Krisztina B., Golovics, Petra Anna, Gönczi, Lóránt, Kristóf, Tünde, Kürti, Zsuzsanna, Lakatos, László, Lakatos, Péter László, Lovász, Barbara Dorottya, Miheller, Pál, Molnár, Tamás, Palatka, Károly, Papp, Mária, Patai, Árpád, Rutka, Mariann, Salamon, Ágnes, Szamosi, Tamás, Szepes, Zoltán, Tóth, Gábor Tamás, Vincze, Áron, Végh, Zsuzsanna   +24 more
core  

Liver Transplantation After Combination Therapy Based on Immune Checkpoint Inhibitors: A Multicenter Retrospective Study of Safety and Efficacy

Organ Medicine, EarlyView.
This multicenter retrospective study assessed preoperative immune checkpoint inhibitor (ICI) therapy in 17 hepatocellular carcinoma patients undergoing liver transplantation. All received at least one cycle of ICI‐based combination therapy before transplant and achieved a 76.5% objective response rate.
Huanquan Chen, Tianxing Dai, Jie Gao, Chuanjiang Li, Huanwei Chen, Feiwen Deng, Nan Ma, Guoying Wang   +7 more
wiley   +1 more source

Biosimilars

Biosimilars present a necessary and timely opportunity for physicians, patients and healthcare systems. If suitably developed clinically, manufactured to the correct standards and used appropriately, they can positively impact on the financial sustainability of healthcare systems.
Tabernero, Josep||, Vyas, Malvika, Giuliani, Rosa, Arnold, Dirk||, Cardoso, Fatima, Casali, Paolo Giovanni||, Cervantes, Andrés||, Eggermont, Alexander||, Eniu, Alexandru, Jassem, Jacek, Pentheroudakis, George||, Peters, Solange, Rauh, Stefan, Zielinski, Christoph C., Stahel, Rolf A., Voest, Emile||, Douillard, Jean-Yves||, McGregor, Keith, Ciardiello, Fortunato   +18 more
openaire   +3 more sources

Glycosimilarity assessment of biotherapeutics 1: quantitative comparison of the N-glycosylation of the innovator and a biosimilar version of etanercept [PDF]

, 2018
K
Borza, Beáta, Guttman, András, Hajba, László, Szekrényes, Ákos, Szigeti, Márton   +4 more
core  

Advancing pharmacometrics in Africa—Transition from capacity development toward job creation

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 407-419, March 2025.
Abstract Trained pharmacometricians remain scarce in Africa due to limited training opportunities, lack of a pharmaceutical product development ecosystem, and emigration to high‐income countries. The Applied Pharmacometrics Training (APT) fellowship program was established to address these gaps and specifically foster job creation for talent retention.
Goonaseelan (Colin) Pillai, Samer Mouksassi, Innocent G. Asiimwe, Craig R. Rayner, Steven Kern, Phumla Sinxadi, Paolo Denti, Eric Decloedt, Catriona Waitt, Bernhards R. Ogutu, Rik de Greef   +10 more
wiley   +1 more source

Safety and Efficacy Assessment of Trastuzumab Emtansine in Indian Patients With Human Epidermal Growth Factor Receptor 2‐Positive Unresectable Locally Advanced or Metastatic Breast Cancer Previously Treated With Trastuzumab and a Taxane: An Open‐Label, Single‐Arm, Phase IV Study

Asia-Pacific Journal of Clinical Oncology, EarlyView.
A phase IV, single‐arm, open‐label, multicenter study assessing the safety and efficacy of trastuzumab emtansine in Indian patients for the treatment of human epidermal growth factor receptor 2 (HER2)‐positive unresectable locally advanced or metastatic breast cancer who received prior treatment with trastuzumab and a taxane.
Sudeep Gupta, Manish Singhal, Shona Nag, Waseem Abbas, Dinesh Chandra Doval, Hari Goyal, Chirag Shah, Ashish Singh, Radheshyam Naik, Nitesh Rohatgi, Poonam Patil, Shyam Aggarwal, Vinod Raina, Vaibhav Watts   +13 more
wiley   +1 more source